EXEL - エクセリクス (Exelixis Inc.) エクセリクス

 EXELのチャート


 EXELの企業情報

symbol EXEL
会社名 Exelixis Inc (エクセリクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エクセチクス(Exelixis Inc.)は癌の低分子療法の開発に取り組むバイオ企業。同社はcabozantinib(カボザンチニブ)(XL184)に資源を投入し、それの開発を集中する。同社は他の化合物製品も有する。カボザンチニブは臨床開発段階にあるMETの阻害剤で、複数の癌の適応症を包含する開発プログラムで査定される。カボザンチニブの臨床プログラムは転移性去勢抵抗性前立腺癌(CRPC)と甲状腺髄様癌の治療に集中し、他のタイプの腫瘍の査定も含む。カボザンチニブは腫瘍の増殖、血管侵入および/または転移のキードライバーであるタンパク質のMET、血管内皮増殖因子受容体2(VEGFR2)、及びトランスフェクション中の再構成(RET)を抑制する。   エクセリクスは米国のバイオ医薬品メ―カ―。主にがん治療のための小分子治療薬の開発、製品化に従事。進行性・転移性甲状腺髄様癌の治療薬「COMETRIO」(カボザンチニブ)に焦点を当てた臨床活動を行う。同社は1994年に設立され、カリフォルニア州サウスサンフランシスコに本社を置く。   
本社所在地 1851 Harbor Bay Parkway Alameda CA 94502 USA
代表者氏名 Stelios Papadopoulos Stelios Papadopoulos
代表者役職名 Independent Chairman of the Board Co-Founder
電話番号 +1 650-837-7000
設立年月日 34639
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 372人
url www.exelixis.com
nasdaq_url https://www.nasdaq.com/symbol/exel
adr_tso
EBITDA EBITDA(百万ドル) 322.48800
終値(lastsale) 17.35
時価総額(marketcap) 5170915196.3
時価総額 時価総額(百万ドル) 5206.68
売上高 売上高(百万ドル) 671.03600
企業価値(EV) 企業価値(EV)(百万ドル) 4727.403
当期純利益 当期純利益(百万ドル) 323.22200
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Exelixis Inc. revenues increased from $179.9M to $398.5M. Net income increased from $34.4M to $203.4M. Revenues reflect Net product revenues increase of 79% to $280.1M Collaboration revenues increase from $23M to $118.3M. Net income benefited from Interest expense decrease from $8.7M (expense) to $0K Interest Income increase of 71% to $4.6M (income).

 EXELのテクニカル分析


 EXELのニュース

   Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders  2021/03/25 09:00:00 Benzinga
SEATTLE and CAMBRIDGE, England, March 25, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019. With funding from RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG), Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day. The company is progressing two clinical stage assets with clinically validated mechanisms of action for neurological diseases. ETX-810, an investigational new chemical entity (NCE) for chronic pain, which acts via the palmitoylethanolamide (PEA) pathway, is being evaluated in two Phase 2a trials in lumbosacral radicular pain (chronic sciatica) and diabetic peripheral neuropathic pain. ETX-155, an investigational next generation neuroactive steroid NCE that acts as a GABA A positive allosteric modulator (PAM), is being evaluated in Phase 1 studies with plans for 2021 trial initiations in multiple indications, including major depressive disorder (MDD), hormone-related mood disorders, and focal onset seizures (FOS). "Most patients with chronic pain and other neuronal excitability disorders struggle immensely to manage their condition with currently available treatments," said Eliem's President and Chief Executive Officer, Bob Azelby . "For many of these patients, the inability to execute day-to-day activities is devastating, and living a normal life can seem out of reach.
   Exelixis, Inc. (NASDAQ:EXEL) Director Sells $944,000.00 in Stock  2021/03/21 09:14:41 Watchlist News
Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber sold 40,000 shares of the stock in a transaction on Monday, March 15th. The stock was sold at an average price of $23.60, for a total value of $944,000.00. Following the completion of the sale, the director now owns 52,718 shares in the company, valued at approximately $1,244,144.80. […]
   Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma  2021/03/18 12:00:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study STELLAR-001 (previously called “XL092-001”), adding three new cohorts that will evaluate the safety and tolerability of XL092, Exelixis’ novel next generation tyrosine kinase inhibitor (TKI), in combination with avelumab (BAVENCIO®), an anti-PD-L1 immune checkpoint inhibito
   Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma  2021/02/26 11:30:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (RCC). The European Commission, which has the authority to approve medicines for the European Union, will n
   Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March  2021/02/25 21:05:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor conferences in March: Cowen 41st Annual Healthcare Conference: Exelixis is scheduled to present at 2:40 PM EST / 11:40 AM PST on Monday, March 1, 2021. Barclays Global Healthcare Conference 2021: Exelixis is scheduled to present at 11:30 AM EST / 8:30 AM PST on Tu
   Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders  2021/03/25 09:00:00 Benzinga
SEATTLE and CAMBRIDGE, England, March 25, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019. With funding from RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG), Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day. The company is progressing two clinical stage assets with clinically validated mechanisms of action for neurological diseases. ETX-810, an investigational new chemical entity (NCE) for chronic pain, which acts via the palmitoylethanolamide (PEA) pathway, is being evaluated in two Phase 2a trials in lumbosacral radicular pain (chronic sciatica) and diabetic peripheral neuropathic pain. ETX-155, an investigational next generation neuroactive steroid NCE that acts as a GABA A positive allosteric modulator (PAM), is being evaluated in Phase 1 studies with plans for 2021 trial initiations in multiple indications, including major depressive disorder (MDD), hormone-related mood disorders, and focal onset seizures (FOS). "Most patients with chronic pain and other neuronal excitability disorders struggle immensely to manage their condition with currently available treatments," said Eliem's President and Chief Executive Officer, Bob Azelby . "For many of these patients, the inability to execute day-to-day activities is devastating, and living a normal life can seem out of reach.
   Exelixis, Inc. (NASDAQ:EXEL) Director Sells $944,000.00 in Stock  2021/03/21 09:14:41 Watchlist News
Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber sold 40,000 shares of the stock in a transaction on Monday, March 15th. The stock was sold at an average price of $23.60, for a total value of $944,000.00. Following the completion of the sale, the director now owns 52,718 shares in the company, valued at approximately $1,244,144.80. […]
   Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma  2021/03/18 12:00:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study STELLAR-001 (previously called “XL092-001”), adding three new cohorts that will evaluate the safety and tolerability of XL092, Exelixis’ novel next generation tyrosine kinase inhibitor (TKI), in combination with avelumab (BAVENCIO®), an anti-PD-L1 immune checkpoint inhibito
   Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma  2021/02/26 11:30:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (RCC). The European Commission, which has the authority to approve medicines for the European Union, will n
   Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March  2021/02/25 21:05:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor conferences in March: Cowen 41st Annual Healthcare Conference: Exelixis is scheduled to present at 2:40 PM EST / 11:40 AM PST on Monday, March 1, 2021. Barclays Global Healthcare Conference 2021: Exelixis is scheduled to present at 11:30 AM EST / 8:30 AM PST on Tu
   Exelixis : Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU | MarketScreener  2021/02/13 18:01:03 MarketScreener
– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy – – Data to be presented during the 2021… | February 13, 2021
   Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU  2021/02/13 18:00:00 Business Wire
Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 2 results for CABOMETYX® (cabozantinib) compared with sunitinib, the current preferred th
   Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors  2021/02/12 22:15:00 Business Wire
Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (N
   Exelixis (NASDAQ:EXEL) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS  2021/02/11 20:46:41 Transcript Daily
Exelixis (NASDAQ:EXEL) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.04, MarketWatch Earnings reports. Exelixis had a net margin of 15.88% and a return on equity of 8.55%. The business had revenue of $270.10 million during the […]
   Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss | Investing.com  2021/02/11 20:40:06 Investing.com
Stocks Analysis by Zacks Investment Research covering: Bristol-Myers Squibb Company, Exelixis Inc, Roche Holding AG Participation, Roche Holding Ltd ADR. Read Zacks Investment Research's latest article on Investing.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エクセリクス EXEL Exelixis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)